<code id='E6E2D0101A'></code><style id='E6E2D0101A'></style>
    • <acronym id='E6E2D0101A'></acronym>
      <center id='E6E2D0101A'><center id='E6E2D0101A'><tfoot id='E6E2D0101A'></tfoot></center><abbr id='E6E2D0101A'><dir id='E6E2D0101A'><tfoot id='E6E2D0101A'></tfoot><noframes id='E6E2D0101A'>

    • <optgroup id='E6E2D0101A'><strike id='E6E2D0101A'><sup id='E6E2D0101A'></sup></strike><code id='E6E2D0101A'></code></optgroup>
        1. <b id='E6E2D0101A'><label id='E6E2D0101A'><select id='E6E2D0101A'><dt id='E6E2D0101A'><span id='E6E2D0101A'></span></dt></select></label></b><u id='E6E2D0101A'></u>
          <i id='E6E2D0101A'><strike id='E6E2D0101A'><tt id='E6E2D0101A'><pre id='E6E2D0101A'></pre></tt></strike></i>

          entertainment

          entertainment

          author:knowledge    Page View:689
          A scientist working at SQZ Biotechnologies in Watertown's Arsenal Yards. -- biotech coverage from STAT
          A scientist working at SQZ Biotechnologies in Watertown, Mass. David L Ryan/Globe Staff

          Next stop: Beacon Hill.

          Governor Maura Healey’s long-awaited plan to double down on state funding for the biotech and medical technology sector came into focus Thursday with the announcement she’ll seek $1 billion over the next decade to reauthorize the state’s 16-year-old life sciences initiative.

          advertisement

          But lawmakers so far are noncommittal on funding the plan. The proposal — dubbed “Life Sciences 3.0″ — is part of a larger economic development bill the Healey administration is expected to file soon. Several expressed support for an industry in which Massachusetts is a leader, but also noted the spending request comes at a time of competing priorities.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more
          Insmed lung disease drug hits target in key Phase 3 trial
          Insmed lung disease drug hits target in key Phase 3 trial

          AdobeAnexperimentaldrugfromInsmedIncorporatedsuccessfullyreducedlungproblemsamongpatientswithanairwa

          read more
          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more

          Merck to buy EyeBio, maker of eye drug, as it grows pipeline

          AdobeLONDON—MercksaidWednesdayitisbuyingophthalmology-focusedstartupEyeBioinadealworthupto$3billion,